Abstract
Critical questions remain concerning many issues involved in the identification of bioequivalent and therapeutically equivalent drugs. They need to be answered, and scientists and clinicians should address these issues, in concert with the FDA, as soon as possible.
MeSH terms
-
Aged
-
Biological Availability
-
Biopharmaceutics*
-
California
-
Humans
-
Legislation, Medical*
-
Pennsylvania
-
Pharmaceutical Preparations / metabolism
-
Therapeutic Equivalency
-
United States
-
United States Food and Drug Administration
Substances
-
Pharmaceutical Preparations